Dutasteride
Avodart · Duagen · GI198745 · GG-745
Last updated
At a glance
Overview
Dutasteride inhibits 5-alpha-reductase and reduces formation of dihydrotestosterone (DHT). Human trials support a hair-growth effect in men with androgenetic alopecia, but deciding whether to use it requires a diagnosis and prescription review. In the United States, Avodart is approved for symptomatic benign prostatic hyperplasia, not hair loss. US prescribing information
A 917-man randomized trial found greater improvement in target-area hair count with dutasteride 0.5 mg daily than finasteride 1 mg daily after 24 weeks. That finding does not make dutasteride the automatic next step for everyone, establish a universal side-effect ranking, or validate use alongside anabolic steroids. Harcha trial
Scope of this review: the editorial text was checked October 1, 2026. Existing dose tiers, risk tags, effectiveness graphics and linked protocol/synergy records are inherited site data and have not been clinically validated by this review. They should not be used to select a treatment or dose. In particular, a fertility concern is not the same as a blanket contraindication for every man planning conception.
Sexual symptoms, mood changes, reproductive plans, pregnancy exposure, interacting medicines and PSA interpretation all deserve discussion. Dutasteride remains in the body for months; its half-life cannot predict when an individual symptom will resolve.
How Dutasteride works
DHT reduction is a mechanism, not a complete outcome#
The US label describes inhibition of type 1 and type 2 5-alpha-reductase, reducing conversion of testosterone to DHT. Blood DHT suppression is a pharmacodynamic measurement; it is not a direct percentage of hair retained or regrown. The label reports a terminal half-life of about five weeks at steady state and detectable concentrations for up to four to six months after stopping. Clinical pharmacology, section 12
Those properties explain why exposure can persist. They do not establish that a twice-weekly schedule retains a stated percentage of daily treatment's cosmetic effect. Nor does the mechanism establish protection from hair loss caused by anabolic-steroid use or justify combining research antiandrogens.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.5–1 mg | Once daily | Documented entry-level range |
| Mid | 1.5–3.5 mg | Once daily | Most commonly studied range |
| High | 3.5–3.5 mg | Once daily | The US Avodart label specifies 0.5 mg once daily for benign prostatic hyperplasia, not a US hair-loss indication. Intermittent schedules have limited hair-loss research; a long half-life does not prove equivalent hair outcomes or lower risk. The numerical dose tiers on this site are not prescribing recommendations. See the evidence review below. |
Cycle length & outcomes
Documented cycle
24–260 weeks
Plateau after
72 wks
Review response and tolerability separately#
Agree on a follow-up plan with the prescriber and use comparable photographs or clinical assessments. A study's 24-week endpoint is not a requirement to tolerate adverse effects for six months. A new shed does not prove that treatment is working.
If symptoms arise, review them promptly. The drug's prolonged elimination can matter when changing treatment, but it supplies neither a guaranteed symptom-recovery date nor a universal “washout” interval for conception. Do not repeatedly stop and restart or change the schedule to chase daily hair counts.
See the hair-treatment review guide for the distinction between planned outcome checks and symptoms requiring earlier attention.
Risks & mistakes
Symptoms and precautions that need attention#
Sexual adverse effects can include reduced libido, erectile dysfunction and ejaculation changes. Breast tenderness or enlargement can occur. The US label notes that sexual adverse reactions may persist after discontinuation and that dutasteride's role in this persistence is unknown. A reassuring short trial cannot supply the frequency of rare or persistent outcomes. Avodart adverse reactions
The May 2026 MHRA update advises people taking dutasteride to contact their healthcare professional as soon as possible for depression or suicidal thoughts, and to seek advice for sexual dysfunction. The dutasteride mood warning is precautionary because evidence is limited; it should not be described as proof of the same risk as finasteride. If there is immediate danger of self-harm, seek emergency help. MHRA guidance
Pregnancy exposure is a fetal risk. Fertility counseling is a different question: the label reports reductions in sperm count, semen volume and motility in a healthy-men study, with uncertainty about the implications for an individual's fertility. Planning conception calls for a prescriber discussion, not an automatic promise that a fixed pause restores fertility.
Dutasteride lowers PSA and changes how results should be interpreted. Tell the clinician arranging a PSA test that you take it; the label calls for evaluation of a confirmed rise and includes a high-grade prostate-cancer warning. Do not self-adjust a laboratory result or interpret it without that context. Blood donation is prohibited during treatment and for at least six months after the last dose under the US label.
Seek urgent help for a serious allergic reaction, including swelling or breathing difficulty. Report a breast lump, nipple discharge or other new concerning change. Review liver disease and potentially interacting medicines before treatment.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
Pharmacokinetic conflicts, competing pathways, or compounded toxicity. Multipliers below 1 indicate the affected axis.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| antagonistic | ×1.00 | ×1.00 | ×1.00 |
Featured in stacks1 curated protocol include Dutasteride
FAQ — Dutasteride
Research & citations
5 studies cited on this page.
Conclusion
Dutasteride has human hair-growth evidence and important prescription precautions. Its greater target-area hair-count improvement in a short trial does not settle the best treatment or schedule for an individual. Use the evidence to discuss diagnosis, expected benefit, adverse effects, reproductive plans and follow-up with a clinician; do not use inherited dose tiers or a proposed steroid-protection stack as a prescription.